A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

  • End date
    Dec 31, 2027
  • participants needed
  • sponsor
    Beijing InnoCare Pharma Tech Co., Ltd.
Updated on 28 October 2022


To evaluate the efficacy of orelabrutinib combined with R-CHOP vs. R-CHOP alone in the treatment of treatment-naїve mantle cell lymphoma.

Condition Treatment-naїve Mantle Cell Lymphoma
Treatment R-CHOP, Orelabrutinib and R-CHOP
Clinical Study IdentifierNCT05051891
SponsorBeijing InnoCare Pharma Tech Co., Ltd.
Last Modified on28 October 2022


Yes No Not Sure

Inclusion Criteria

65 < age <80, or 60 ≤ age ≤65 and is ineligible for autologous stem cell transplantation as assessed by the investigator
Histopathological confirmed MCL and either expression of cyclin D1 or t (11;14) chromosomal translocation (in association with CD20). The verification will be based on central review of the local pathology report
No previous systemic treatment for MCL
ECOG physical strength score is 0-2
Expected survival time >6 months
Voluntary written informed consent prior to screening

Exclusion Criteria

Uncontrolled or significant cardiovascular diseases
History of stroke or intracranial hemorrhage within 6 months before first administration of study treatment
Any mental or cognitive impairments which may limit the subject 's understanding and execution of informed consent as well as study compliance
Pregnant or breastfeeding women and those who do not agree to take contraceptive measures
Conditions in which a potentially life-threatening illness or severe organ dysfunction is not considered appropriate by the investigator
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note